[Regression of the cerebellar syndrome under long-term administration of 5-HTP or the combination of 5-HTP and benserazide. 26 cases quantified and treated using computer methods].
A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values related to the major symptoms, is proposed. 21 patients with heredo-ataxias were treated for 12 months with high doses (16 mg/kg/day) of D-L-5-HTP, L-5-HTP or the association D-L-5-HTP (16 mg/kg/day)-Benserazide(6 mg/kg/day). A computerized processing of the data obtained by regular examination was performed. The ataxia showed a significant regression at the 12th month, mainly in the static performances and in the speed of speech. L-5-HTP appeared to be more active than D-L-5-HTP. The regression of the cerebellar ataxia was also observed in non degenerative conditions such as multiple sclerosis and surgical injury of the anterior lobe vermis, showing that 5-HTP was active on the cerebellar syndrome in general. The regression of the cerebellar ataxia was very slow in inherited diseases and continued for 2 or 4 months after the treatment stopped. A serotoninergic cerebellar control of motricity is discussed.
D006916:5-Hydroxytryptophan / Q000627:therapeutic use*; D001545:Benserazide / Q000627:therapeutic use*; D002524:Cerebellar Ataxia / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D003201:Computers; D004359:Drug Therapy, Combination; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007700:Kinetics; D013997:Time Factors
D006834:Hydrazines; D001545:Benserazide; D006916:5-Hydroxytryptophan
Régression du syndrome cérébelleux sous administration à long terme de 5-HTP ou de l'association 5-HTP-bensérazide.